



Avian Influenza: Public Health Response

Wisconsin Virology Conference
June 11, 2025

Jordan Mason, DVM, MPH
Communicable Disease Epi Section Manager
Wisconsin Department of Health Services



Agenda

- Routine Influenza Surveillance
- Avian Influenza in People
- Novel Influenza Surveillance
- Prevention

Routine Influenza Surveillance



Reportable Diseases



Laboratory Surveillance



Wastewater Surveillance




Reportable Diseases



- Influenza-associated hospitalizations
- Influenza-associated pediatric deaths
- Novel Influenza A infections


Reportable Diseases

Weekly influenza-associated hospitalizations by influenza season, WEDSS



Statewide

Percent (%) deaths associated with COVID-19, influenza, RSV, or pneumonia



Laboratory Surveillance



January 25, 2025

This dashboard shows respiratory virus activity and trajectories for the week ending on January 25, 2025.



To view data for a specific Wisconsin public health region, click below.

Statewide

Overall respiratory illness activity based on emergency department visits (Statewide)

This represents




Virus species




Wisconsin positive influenza results and subtypes by PCR, NREVSS

A(H1N1) A(H3N2) A (unknown subtype) Influenza B % Positive for influenza



3-week average percent (%) of reported test results positive for selected viruses by week. Data are interactive. **Hover over lines** to see more information and use options featured below.



Wastewater Surveillance



Respiratory Wastewater Surveillance in Wisconsin

Select a virus below to view its data

Influenza A

Influenza B


RSV

Not Detected Low Medium High

Select a community below to view its data

Select a Date (copy)
(Multiple values)


Influenza A Levels by Community




Avian Influenza in People




Influenza Viruses




— Human influenza viruses



— Avian influenza viruses



— Swine influenza viruses




— Other animals with periodic outbreaks

Examples: Horses, cats, dogs, seals, ostriches, pandas, penguins, ferrets/mink

What is Avian Influenza?

- Influenza A viruses that occur naturally in **wild birds around the world** and can cause disease in wild and domestic birds
- Disease varies in severity depending on the strain and species affected





High vs Low Path Influenza


- HPAI = Highly pathogenic avian influenza
- LPAI = Low pathogenicity avian influenza
- The categories refer to viral molecular characteristics and morbidity and mortality in **chickens in a laboratory setting**

Spread to Other Animals


- Many non-avian species are potentially susceptible to HPAI
- HPAI and LPAI do not refer to or predict severity of illness in humans



Symptoms



Conjunctivitis



Fever



Cough



Influenza-like
Illness

Situation summary of confirmed and probable human cases since 2024

Confirmed Cases

Probable Cases

State or territory


National

National Total Cases: 70

Cases	Exposure Source
41	Dairy Herds (Cattle)*
24	Poultry Farms and Culling Operations*
2	Other Animal Exposure†
3	Exposure Source Unknown‡

NOTE: One additional case was previously detected in a poultry worker in Colorado in 2022. Louisiana reported the first H5 bird flu death in the U.S.

*Exposure Associated with Commercial Agriculture and Related Operations
†Exposure was related to other animals such as backyard flocks, wild birds, or other mammals
‡Exposure source was not able to be identified



Novel Influenza Surveillance



Surveillance: Monitoring

- Monitoring for illness among people with a known exposure to infected animals (highest risk).
- Monitoring for illness in contacts of human cases.



Surveillance: Testing

Surveillance for infection among people without a known exposure:

- Subtyping of influenza samples
- Wastewater surveillance
- Syndromic surveillance tools



National flu surveillance (since February 25, 2024)

Specimens tested

198,286+ specimens tested that would have detected influenza A(H5) or other novel influenza viruses

Human cases

6 case detected through national flu surveillance

Targeted H5 surveillance (since March 24, 2024)

Total people monitored

17,500+ after exposure to infected animals


Total people tested

880+ after exposure to infected animals

Human cases

64 cases detected through targeted H5 surveillance

Surveillance: Wastewater




Select a detection type below to add or remove it from the map.

● H5 Detection ● No Detection ● No Samples in Last Week

Prevention




Stages of Emergence



World Health Organization global framework to define and guide studies into the origins of emerging and re-emerging pathogens with epidemic and pandemic potential; World Health Organization; 2024


Risk Assessment Considerations

- No evidence of human-to-human transmission in the U.S.
- Most U.S. cases have resulted in mild symptoms
- All human infections have been susceptible to antiviral




Risk Assessment Considerations

- Current candidate vaccine virus likely still effective
- Few sporadic cases identified without a risk factor




Prevention

- Protect **people who work with animals or animal products** on daily basis
- Protect **workers responding** to animal outbreaks
- Protect **contacts of a case patient** (health care, household, occupational)



Prevention

- Protect the public from exposure through food
- Minimize opportunities for co-infections



Worker Protection

- Decrease human exposure to sick animals
- Personal protective equipment (PPE) guidance and availability
- Identify exposed workers
- Increase outreach and information sharing




Public Health Role



Education and PPE for exposed workers



Monitor exposed workers for signs of influenza



Arrange testing and post-exposure prophylaxis for sick workers

Key Points

- ✓ Risk to public remains low
- ✓ People with contact with infected animals are at higher risk
- ✓ Case-based control measure strategy:
 - Isolation, treatment
 - Post-exposure prophylaxis of contacts
- ✓ Surveillance and testing critical

Questions?

Jordan Mason, DVM, MPH
jordan.mason@dhs.wisconsin.gov

